Literature DB >> 7105029

CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival.

B K Bhuyan, K A Newell, S L Crampton, D D Von Hoff.   

Abstract

CC-1065 (NSC 298223) is the most cytotoxic agent tested against cells in culture in our laboratory. The 50% lethal doses for exponentially growing B16 melanoma and Chinese hamster ovary cells were 0.44 and 0.14 ng/ml, respectively, as compared to 35 and 500 ng/ml for Adriamycin. In the human tumor-cloning assay, 1-hr exposure to CC-1065 (0.1 ng/ml) caused greater than or equal to 50% lethality in a broad spectrum of tumors. The dose-survival curves for B16 and Chinese hamster ovary cells were characterized by an initial shoulder followed by an exponential decline with increasing dose. CC-1065 was more lethal to exponentially growing B16 cells (50% lethal dose = 0.44 ng/ml) than to plateau-phase cells (50% lethal dose = 1.2 ng/ml). CC-1065 inhibited DNA synthesis much more than did RNA or protein synthesis. After a 2-hr incubation with drug, inhibition of DNA synthesis was low immediately (0 hr) after drug exposure and reached maximum inhibition about 20 hr later. The doses for 50% inhibition of growth (0.18 ng/ml), survival (0.44 ng/ml), and DNA synthesis (0.15 ng/ml) were in the same range, whereas RNA synthesis was inhibited 50% at a much higher dose (5 ng/ml).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105029

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Theoretical study of the sequence specificity in the covalent binding of the antitumor drug CC-1065 to DNA.

Authors:  K Zakrzewska; M Randrianarivelo; B Pullman
Journal:  Nucleic Acids Res       Date:  1987-07-24       Impact factor: 16.971

2.  DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin.

Authors:  M Broggini; H M Coley; N Mongelli; E Pesenti; M D Wyatt; J A Hartley; M D'Incalci
Journal:  Nucleic Acids Res       Date:  1995-01-11       Impact factor: 16.971

3.  Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex.

Authors:  D R Needham-VanDevanter; L H Hurley; V L Reynolds; N Y Theriault; W C Krueger; W Wierenga
Journal:  Nucleic Acids Res       Date:  1984-08-10       Impact factor: 16.971

4.  Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

Authors:  N M Lopes; E G Adams; T W Pitts; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Synergistic combination of menogarol and melphalan and other two drug combinations.

Authors:  B K Bhuyan; E G Adams; M Johnson; S L Crampton
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant.

Authors:  R K Butryn; K S Smith; E G Adams; I Abraham; J Stackpole; K E Sampson; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects.

Authors:  B K Bhuyan; K S Smith; E G Adams; T L Wallace; D D Von Hoff; L H Li
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug.

Authors:  Yuqiang Wang; Huiling Yuan; Susan C Wright; Hong Wang; James W Larrick
Journal:  BMC Chem Biol       Date:  2001

9.  Synthesis and cytotoxicity of a biotinylated CC-1065 analogue.

Authors:  Yuqiang Wang; Huiling Yuan; Susan C Wright; Hong Wang; James W Larrick
Journal:  BMC Chem Biol       Date:  2002

10.  Differential effect of duocarmycin A and its novel derivative DU-86 on DNA strand breaks in HeLa S3 cells.

Authors:  A Okamoto; A Asai; H Saito; M Okabe; K Gomi
Journal:  Jpn J Cancer Res       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.